ArticleESC heart failure2016
Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study.
Article in ESC heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.European heart journal · 2021Trial
- Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial.Journal of the American Heart Association · 2020Trial
- Impact of iron deficiency on health-related quality of life and functional status in adults with chronic heart failure in Nigeria.BMC cardiovascular disorders · 2025Article
- The Impact of Intravenous Ferric Carboxymaltose on Reverse Electrical Remodeling Following Cardiac Resynchronization Therapy.Acta Cardiologica Sinica · 2024Article
- Iron Deficiency: A Silent Threat in Patients With Heart Failure With Reduced Ejection Fraction.Cureus · 2024Article
- Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update.Cardiovascular drugs and therapy · 2023Review
- Article
- Why Iron Deficiency in Acute Heart Failure Should Be Treated: A Real-World Clinical Practice Study.Life (Basel, Switzerland) · 2022Article
- Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action.Journal of internal medicine · 2022Review
- Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.ESC heart failure · 2022Article
- The Effect of Iron Deficiency on Cardiac Function and Structure in Heart Failure with Reduced Ejection Fraction.Cardiac failure review · 2022Review
- Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology.Journal of clinical medicine · 2021Review
- Iron deficiency in heart failure.ESC heart failure · 2021Review
- Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents.Frontiers in medicine · 2021Review
- Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial.ESC heart failure · 2020Article
- Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction.Journal of clinical medicine · 2020Article
- Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.ESC heart failure · 2019Article
- The difference in referencing in Web of Science, Scopus, and Google Scholar.ESC heart failure · 2019Article
- Open access efforts begin to bloom: ESC Heart Failure gets full attention and first impact factor.ESC heart failure · 2019Review
- Structural and functional abnormalities in iron-depleted heart.Heart failure reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIn patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, treatment with intravenous iron has shown a clinical improvement regardless of anaemic status. Cardiac magnetic resonance (CMR) T2* sequence has shown a potential utility for evaluating myocardial iron deficiency. We aimed to evaluate whether T2* sequence significantly changes after ferric carboximaltose (FCM) administration, and if such changes correlate with changes in left ventricle ejection fraction (LVEF). METHODS AND
resultsIn this pilot study, we included eight patients with chronic symptomatic (New York Heart Association II-III) HFrEF and iron deficiency. A CMR, including T2* analysis, was performed before and at a median of 43 days (interquartile range = 35-48) after intravenous FCM administration. Pearson or Spearman correlation coefficient (r) was used for bivariate contrast as appropriate. A partial correlation analysis was performed between ΔLVEF and ΔT2* while controlling for anaemia status at baseline. Anaemia was present in half of patients. After FCM administration, T2* decreased from a median of 39.5 (35.9-48) to 32 ms (32-34.5),
conclusionsIn a small sample of patients with HFrEF and iron deficiency, myocardial iron repletion assessed by CMR was associated to left ventricular remodelling. Further studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.